{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T18:35:19Z","timestamp":1757615719316,"version":"3.44.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.lungcan.2025.108701","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T02:17:51Z","timestamp":1754446671000},"page":"108701","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A treatment-impact model of alectinib for the prediction of recurrence and associated costs in treating resectable ALK+ non-small cell lung cancer"],"prefix":"10.1016","volume":"207","author":[{"given":"Amy L.","family":"Cummings","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse","family":"Sussell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3403-3295","authenticated-orcid":false,"given":"Katherine L.","family":"Rosettie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadoua El","family":"Moustaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarika","family":"Ogale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celina","family":"Ngiam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Jovanoski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1700-6831","authenticated-orcid":false,"given":"Melina","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2025.108701_b0005","unstructured":"American Cancer Society, Facts & Figures 2019, 2019. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2019\/cancer-facts-and-figures-2019.pdf. (Accessed October 11, 2024)."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108701_b0010","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","article-title":"Update of incidence, prevalence, survival, and initial treatment in patients with non\u2013small cell lung cancer in the US","volume":"7","author":"Ganti","year":"2021","journal-title":"JAMA Oncol."},{"issue":"9202","key":"10.1016\/j.lungcan.2025.108701_b0015","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(00)82038-3","article-title":"Lung cancer","volume":"355","author":"Hoffman","year":"2000","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.lungcan.2025.108701_b0020","first-page":"372","article-title":"Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signatures","volume":"2","author":"Carnio","year":"2013","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108701_b0025","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.xjon.2022.03.004","article-title":"Survival after recurrence following surgical resected non-small cell lung cancer: a multicenter, prospective cohort study","volume":"10","author":"Takenaka","year":"2022","journal-title":"JTCVS Open"},{"issue":"4","key":"10.1016\/j.lungcan.2025.108701_b0030","article-title":"Economic burden of recurrence among resected medicare patients with early stage NSCLC","volume":"4","author":"Lee","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108701_b0035","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s41669-017-0045-0","article-title":"The economic burden of small cell lung cancer: a systematic review of the literature","volume":"2","author":"Enstone","year":"2018","journal-title":"PharmacoEcon. Open"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108701_b0040","first-page":"255","article-title":"Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States","volume":"28","author":"Zhang","year":"2022","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108701_b0045","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1200\/JCO.22.00051","article-title":"Adjuvant systemic therapy and adjuvant radiation therapy for stage I-IIIA completely resected non-small-cell lung cancer: ASCO guideline rapid recommendation update","volume":"40","author":"Pisters","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108701_b0050","doi-asserted-by":"crossref","unstructured":"NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data, Lancet 383(9928) (2014) 1561-1571.","DOI":"10.1016\/S0140-6736(13)62159-5"},{"issue":"36","key":"10.1016\/j.lungcan.2025.108701_b0055","doi-asserted-by":"crossref","first-page":"24470","DOI":"10.18632\/oncotarget.25327","article-title":"Outcomes of neoadjuvant and adjuvant chemotherapy in stage 2 and 3 non-small cell lung cancer: an analysis of the National Cancer Database","volume":"9","author":"MacLean","year":"2018","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108701_b0060","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40487-024-00268-5","article-title":"Real-world treatment patterns and survival among patients with stage I-III, non-squamous, non-small cell lung cancer receiving surgery as primary treatment","volume":"12","author":"Seung","year":"2024","journal-title":"Oncol. Ther."},{"issue":"7153","key":"10.1016\/j.lungcan.2025.108701_b0065","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4\u2013ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.lungcan.2025.108701_b0070","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1097\/JTO.0b013e3181c4dedb","article-title":"ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer","volume":"4","author":"Solomon","year":"2009","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108701_b0075","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s10555-015-9592-y","article-title":"Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?","volume":"34","author":"Toyokawa","year":"2015","journal-title":"Cancer Metastasis Rev."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108701_b0080","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.jtho.2018.07.001","article-title":"The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib","volume":"13","author":"Patil","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"Supplement_4","key":"10.1016\/j.lungcan.2025.108701_b0085","article-title":"Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2025.108701_b0090","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1200\/EDBK_242209","article-title":"What it takes to improve a first-generation inhibitor to a second- or third-generation small molecule","volume":"39","author":"Rodon Ahnert","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"9","key":"10.1016\/j.lungcan.2025.108701_b0095","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.20.03570","article-title":"Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update","volume":"39","author":"Hanna","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108701_b0100","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.lungcan.2025.108701_b0105","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann. Oncol."},{"issue":"14","key":"10.1016\/j.lungcan.2025.108701_b0110","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108701_b0115","unstructured":"Alecensa (alectinib) [package insert]. Genentech, Inc., 2024."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108701_b0120","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1002\/cam4.5462","article-title":"Estimating recurrences prevented and costs avoided with atezolizumab in early non-small cell lung cancer in the United States","volume":"12","author":"Sharma","year":"2023","journal-title":"Cancer Med."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108701_b0125","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1007\/s12325-023-02554-6","article-title":"Impact of pertuzumab and ado-trastuzumab emtansine on cumulative avoidance of recurrence among women treated for locally advanced, inflammatory, or early-stage nonmetastatic HER2-positive breast cancer in the United States","volume":"40","author":"Sussell","year":"2023","journal-title":"Adv. Ther."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108701_b0130","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jval.2015.06.003","article-title":"Estimated life-years saved in women with HER2-positive metastatic breast cancer receiving first-line trastuzumab and pertuzumab in the United States","volume":"18","author":"Danese","year":"2015","journal-title":"Value Health"},{"issue":"24","key":"10.1016\/j.lungcan.2025.108701_b0135","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1002\/cncr.34479","article-title":"Annual report to the nation on the status of cancer, part 1: National cancer statistics","volume":"128","author":"Cronin","year":"2022","journal-title":"Cancer"},{"issue":"16_suppl","key":"10.1016\/j.lungcan.2025.108701_b0140","doi-asserted-by":"crossref","first-page":"8074","DOI":"10.1200\/JCO.2024.42.16_suppl.8074","article-title":"ALK testing patterns in early-stage non-small cell lung cancer: a real-world evidence study","volume":"42","author":"Leal","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108701_b0145","unstructured":"National Program of Cancer Registries and Surveillance, Epidemiology, and End Results Program SEER*Stat Database: NPCR and SEER Incidence \u2013 U.S. Cancer Statistics 2001\u20132018 Public Use Research Database, 2020 submission (2001\u20132018), in: US Department of Health and Human Services (Ed.) 2021."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108701_b0150","doi-asserted-by":"crossref","first-page":"337","DOI":"10.21037\/tlcr-22-631","article-title":"Early-stage anaplastic lymphoma kinase (ALK)-positive lung cancer: a narrative review","volume":"12","author":"Chen","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108701_b0155","unstructured":"E.M. Systems, National Oncology Data Alliance, 2024."},{"key":"10.1016\/j.lungcan.2025.108701_b0160","doi-asserted-by":"crossref","first-page":"6765","DOI":"10.2147\/CMAR.S213553","article-title":"Ultra-late recurrence of non-small cell lung cancer over 10 years after curative resection","volume":"11","author":"Sonoda","year":"2019","journal-title":"Cancer Manag. Res."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108701_b0165","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/COC.0000000000000816","article-title":"Cost-effectiveness analysis of ado-trastuzumab emtansine (T-DM1) for the adjuvant treatment of patients with residual invasive HER2+ early breast cancer in the United States","volume":"44","author":"Sussell","year":"2021","journal-title":"Am. J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108701_b0170","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jval.2016.04.011","article-title":"Accounting for cured patients in cost-effectiveness analysis","volume":"20","author":"Othus","year":"2017","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.lungcan.2025.108701_b0175","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1016\/j.cllc.2017.05.005","article-title":"Comparison of radiotherapy and chemoradiotherapy for locoregional recurrence of non-small-cell lung cancer developing after surgery","volume":"18","author":"Nakamichi","year":"2017","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108701_b0180","unstructured":"C. Enviza, CancerMPact Patient Metrics, 2023."},{"key":"10.1016\/j.lungcan.2025.108701_b0185","doi-asserted-by":"crossref","unstructured":"CADTH Reimbursement Reviews and Recommendations, Atezolizumab (Tecentriq): CADTH reimbursement recommendation: Indication: As monotherapy for adjuvant treatment following resection and platinum-based chemotherapy for patients with non\u2013small cell lung cancer whose tumours have programmed death-ligand 1 expression on 50% or more of tumour cells, Canadian Agency for Drugs and Technologies in Health, Ottawa (ON), 2022.","DOI":"10.51731\/cjht.2022.523"},{"key":"10.1016\/j.lungcan.2025.108701_b0190","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med. Res. Method."},{"key":"10.1016\/j.lungcan.2025.108701_b0195","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2147\/CEOR.S132259","article-title":"A retrospective analysis of delays in the diagnosis of lung cancer and associated costs","volume":"9","author":"Gildea","year":"2017","journal-title":"Clinicoecon. Outcomes Res."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108701_b0200","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/cam4.1896","article-title":"Lung cancer costs by treatment strategy and phase of care among patients enrolled in Medicare","volume":"8","author":"Sheehan","year":"2019","journal-title":"Cancer Med."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108701_b0205","article-title":"Estimating productivity loss from breast and non-small-cell lung cancer among working-age patients and unpaid caregivers: a survey study using the multiplier method","volume":"7","author":"Chiu","year":"2022","journal-title":"MDM Policy Pract."},{"key":"10.1016\/j.lungcan.2025.108701_b0210","unstructured":"US Bureau of Labor Statistics, 2023. Civilian labor force participation rate by age, sex, race, and ethnicity. Table 3.3 Civilian labor force participation rates by age, sex, race, and ethnicity, 2002, 2012, 2022, and projected 2032, 2024. https:\/\/www.bls.gov\/emp\/tables\/civilian-labor-force-participation-rate.htm. (Accessed October 14 2024)."},{"issue":"18","key":"10.1016\/j.lungcan.2025.108701_b0215","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108701_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102179","article-title":"Immunotherapy in non-small cell lung cancer harbouring driver mutations","volume":"96","author":"Addeo","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.lungcan.2025.108701_b0225","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/03007995.2023.2167442","article-title":"Projecting overall survival in health-economic models: uncertainty and maturity of data","volume":"39","author":"Roze","year":"2023","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.lungcan.2025.108701_b0230","unstructured":"AnalySource: Premier access to the first databank drug pricing database, 2024. https:\/\/www.analysource.com\/. (Accessed February 2024)."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108701_b0235","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/j.athoracsur.2020.07.048","article-title":"Initial and longitudinal cost of surgical resection for lung cancer","volume":"111","author":"Cowper","year":"2021","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.lungcan.2025.108701_b0240","unstructured":"S. McMorrow, J. Holohan, R.A. Berenson, Commercial health insurance markups over Medicare prices for physician services vary widely by specialty, 2021. https:\/\/www.urban.org\/research\/publication\/commercial-health-insurance-markups-over-medicare-prices-physician-services-vary-widely-specialty. (Accessed October 21, 2021)."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108701_b0245","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L Trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108701_b0250","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","article-title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir. Med."},{"issue":"25","key":"10.1016\/j.lungcan.2025.108701_b0255","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108701_b0260","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jtho.2022.08.018","article-title":"Efficacy of brigatinib in patients with advanced ALK-positive NSCLC who progressed on alectinib or ceritinib: ALK in Lung cancer Trial of brigAtinib-2 (ALTA-2)","volume":"17","author":"Ou","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"22","key":"10.1016\/j.lungcan.2025.108701_b0265","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1200\/JCO.2017.77.4794","article-title":"Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer","volume":"36","author":"Solomon","year":"2018","journal-title":"J. Clin. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225005938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225005938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T14:41:10Z","timestamp":1757083270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225005938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":53,"alternative-id":["S0169500225005938"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108701","relation":{},"ISSN":["0169-5002"],"issn-type":[{"type":"print","value":"0169-5002"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A treatment-impact model of alectinib for the prediction of recurrence and associated costs in treating resectable ALK+ non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108701","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108701"}}